Status:
UNKNOWN
Catecholamines Level in Vitiligo Patients Before and After Excimer Light
Lead Sponsor:
Assiut University
Conditions:
Vitiligo, Generalized
Eligibility:
All Genders
Brief Summary
Vitiligo is an acquired cutaneous disorder of pigmentation, with a 1-2% incidence worldwide, without predilection for sex or race. People affected by vitiligo have a vast reduction of quality of life,...
Detailed Description
Despite much research, the etiology of vitiligo and the causes of melanocyte death are not clear. Conventionally, there have been three hypotheses to explain the pathogenesis of vitiligo: neural, immu...
Eligibility Criteria
Inclusion
- Patients with clinically stable non-segmental vitiligo of different ages and sex treated with excimer light
Exclusion
- Pregnant and lactating women.
- Personal history of hypertrophic scarring, melanoma or other skin cancer.
- Immunosuppression or taking immunosuppressive or photosensitizing drugs, and phototherapy or any other vitiligo treatment during the last 3 months.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04803461
Start Date
April 1 2021
End Date
September 30 2022
Last Update
March 17 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.